Dr. Assaf Mizrahi is a distinguished clinical microbiologist and currently serves as the Associate Head of the Clinical Microbiology Department at Groupe Hospitalier Paris Saint Joseph. He is an active member of the research unit "Antibiotics Dysbiosis and Infectious Risk" at UMR 1319, Institut Micalis, Université Paris-Saclay, INRAe, AgroParisTech. Dr. Mizrahi completed his PharmD with a specialization in clinical microbiology in 2012 at the University of Paris René Descartes. He further pursued a PhD, which he obtained in September 2017, focusing on the "Host immune responses to Clostridioides difficile infections" at the UBaPS unit and the IABV laboratory in the Pasteur Institute. His extensive research in the clinical microbiology and infectious diseases area is highlighted by over 50 publications, with a significant impact in the field, reflected by an h-index of 18 and an i10-index of 27. Dr. Mizrahi's work has substantially contributed to the understanding of immune responses, clinical impact of diagnostics, and antibiotic treatment optimization, with recent studies expanding into the gut microbiota.
Dr. Assaf Mizrahi is a distinguished clinical microbiologist and currently serves as the Associate Head of the Clinical Microbiology Department at Groupe Hospitalier Paris Saint Joseph. He is an active member of the research unit "Antibiotics Dysbiosis and Infectious Risk" at UMR 1319, Institut Micalis, Université Paris-Saclay, INRAe, AgroParisTech. Dr. Mizrahi completed his PharmD with a specialization in clinical microbiology in 2012 at the University of Paris René Descartes. He further pursued a PhD, which he obtained in September 2017, focusing on the "Host immune responses to Clostridioides difficile infections" at the UBaPS unit and the IABV laboratory in the Pasteur Institute. His extensive research in the clinical microbiology and infectious diseases area is highlighted by over 50 publications, with a significant impact in the field, reflected by an h-index of 18 and an i10-index of 27. Dr. Mizrahi's work has substantially contributed to the understanding of immune responses, clinical impact of diagnostics, and antibiotic treatment optimization, with recent studies expanding into the gut microbiota.